AbCellera Biologics (ABCL) PT Lowered to $32 at BMO Capital
Tweet
Share
E-mailGet Alerts ABCL Hot Sheet
Price: $11.12 -0.71%
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Join SI Premium – FREE
BMO Capital analyst Gary Nachman lowered the price target on AbCellera Biologics (NASDAQ: ABCL) to $32.00 (from $40.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Marvell (MRVL) PT Raised to $225 at TD Cowen
- CrowdStrike (CRWD) PT Raised to $250 at Benchmark Ahead of Q2 Results
- Gartner (IT) PT Lowered to $206 at BMO Capital, adjusting estimates
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
